Lakefront Biotherapeutics American Depositary Shares
LKFT
102 hedge funds and large institutions have $1.11B invested in Lakefront Biotherapeutics American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 12 closing their positions.
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
12% more capital invested
Capital invested by funds: $993M → $1.11B (+$119M)
11% more funds holding
Funds holding: 92 → 102 (+10)
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
0.28% more ownership
Funds ownership: 12.87% → 13.15% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less call options, than puts
Call options by funds: $16.8M | Put options by funds: $23.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bessemer Group
Woodbridge,
New Jersey
|
+$44.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.4M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$6.06M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$2.97M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$20.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$14.8M |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$10.3M |
| 4 |
DM
Deerfield Management
New York
|
-$9.01M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$8.18M |
LKFT Hedge Fund Activity: Q2 2019 in Review
102 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2019, worth a combined $1.11B — up 12% from $993M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LKFT positions and 12 closed out — a net gain of 10 holders — while 32 added to existing stakes and 29 trimmed.
The largest buyer was Bessemer Group, opening a new position worth an estimated $44.6M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $20.6M sold.
- 102 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2019, up from 92 in Q1 2019.
- Funds reported $1.11B of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2019, up 12% quarter-over-quarter.
- 22 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2019 and 12 closed out, a net change of +10 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2019 was Bessemer Group, an estimated $44.6M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2019 was Alkeon Capital Management, an estimated $20.6M sold.
Based on aggregated 13F filings for Q2 2019.